Background: Serum C-reactive protein (CRP) is an established biomarker for acute inflammation and has been identified as a prognostic indicator for hepatocellular carcinoma (HCC). However, the significance of the serum CRP level, specifically in HCC patients treated with lenvatinib, remains unclear. Methods: We retrospectively analyzed 125 HCC patients who received lenvatinib treatment at six centers. Clinical characteristics were assessed to identify clinical associations between serum CRP and HCC prognosis. Results: The median overall serum CRP level was 0.29 mg/dL. The cohort was divided into two groups: the low-CRP group with a serum CRP < 0.5 mg/dL and the high-CRP group with a serum CRP ≥ 0.5 mg/dL. The low-CRP group exhibited significantly longer overall survival (OS) than the high-CRP group (22.9 vs. 7.8 months,p< 0.001). No significant difference was observed for progression-free survival (PFS) between the high- and low-CRP groups (9.8 vs. 8.4 months,p= 0.411), while time-to-treatment failure (TTF) was significantly longer in the low-CRP group (8.5 vs. 4.4 months,p= 0.007). The discontinuation rate due to poor performance status was significantly higher in the high-CRP group (p< 0.001). Conclusion: A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.
背景：血清C反应蛋白（CRP）是公认的急性炎症生物标志物，并已被确定为肝细胞癌（HCC）的预后指标。然而，血清CRP水平在特定接受乐伐替尼治疗的HCC患者中的临床意义尚不明确。方法：我们回顾性分析了来自六个中心的125例接受乐伐替尼治疗的HCC患者。通过评估临床特征，探讨血清CRP水平与HCC预后的临床关联。结果：全组患者血清CRP中位水平为0.29 mg/dL。根据血清CRP水平将队列分为两组：低CRP组（血清CRP < 0.5 mg/dL）和高CRP组（血清CRP ≥ 0.5 mg/dL）。低CRP组的总生存期（OS）显著长于高CRP组（22.9个月 vs. 7.8个月，p < 0.001）。两组间的无进展生存期（PFS）无显著差异（9.8个月 vs. 8.4个月，p = 0.411），而低CRP组的治疗失败时间（TTF）显著更长（8.5个月 vs. 4.4个月，p = 0.007）。高CRP组因体能状态不佳而终止治疗的比例显著更高（p < 0.001）。结论：基线血清CRP水平超过0.5 mg/dL被确定为接受乐伐替尼治疗的HCC患者的不良预后因素。
肿瘤(癌症)患者之家